Traded Jul 7, 2026 · Filed Jul 9, 2026
The boss of ResMed| sold $1.09M of ResMed| shares. It was planned long ago, so it says very little.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$1,090,771
Shares × reported transaction price
on the day of results (Jul 7, 2026), 30 days before results of Aug 6, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $219.75 on Jul 7, 2026, 20% above its 52-week low and 25% below its high, after a 5% rise over the previous 30 trading days
52-week range $182.82 (Jun 2, 2026) to $293.73 (Aug 22, 2025), 33% of the way up, from 251 adjusted closes. 30 trading days earlier: $208.98 on May 21, 2026. Describes the past only, not a forecast
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | -2.4% | -1.5% | -0.8% |
| 30 days | +7.9% | +2.4% | +5.5% |
Past results only. Not a forecast.
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
Director sold ~$1.8M of ResMed|
Scheduled in advanceHeld by the filer's joint per the disclosure. Disclosed 824 days after the transaction; reported as an official range, not an exact amount.
Congress trade
